Pinned straw:
I dont like to get too excited about quarterlies and over extrapolate any nascent trends, especially compared to a poor comp.
the significant changes for me were they guided on GP 59-60% vrs the 58-59%, i had pencilled in, the CFO guides to zero net interest expense for fy25 compared to $55m last year, RMD does throw different stuff in this line like FX and other one offs, but it is a big delta, plus some better cost control. these all lead to a better fy25 number than expected for me +6-7%. Everything running their way on this one. long may it last
held
ResMed = monster with fangs.
Putting more distance between it and the rest of my portfolio, and I welcome it :)
Fantastic results @Karmast. Both %GM expansion and operating leverage are impressive, which shows the restructure is delivering as intended. Such a well run global leader!